These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 22993227

  • 1. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.
    Espígol-Frigolé G, Corbera-Bellalta M, Planas-Rigol E, Lozano E, Segarra M, García-Martínez A, Prieto-González S, Hernández-Rodríguez J, Grau JM, Rahman MU, Cid MC.
    Ann Rheum Dis; 2013 Sep 01; 72(9):1481-7. PubMed ID: 22993227
    [Abstract] [Full Text] [Related]

  • 2. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.
    Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, Queralt C, Grau JM, Urbano-Márquez A, Palacín A, Colomer D, Cid MC.
    Rheumatology (Oxford); 2004 Mar 01; 43(3):294-301. PubMed ID: 14679293
    [Abstract] [Full Text] [Related]

  • 3. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.
    Braun N, Fritz P, Rieth A, Schroth W, Kimmel M, Biegger D, Zakim D, Alscher MD.
    J Rheumatol; 2009 Oct 01; 36(10):2269-76. PubMed ID: 19684157
    [Abstract] [Full Text] [Related]

  • 4. Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis.
    Ciccia F, Rizzo A, Guggino G, Cavazza A, Alessandro R, Maugeri R, Cannizzaro A, Boiardi L, Iacopino DG, Salvarani C, Triolo G.
    Rheumatology (Oxford); 2015 Sep 01; 54(9):1596-604. PubMed ID: 25862016
    [Abstract] [Full Text] [Related]

  • 5. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis.
    Cid MC, Hoffman MP, Hernández-Rodríguez J, Segarra M, Elkin M, Sánchez M, Vilardell C, García-Martínez A, Pla-Campo M, Grau JM, Kleinman HK.
    Rheumatology (Oxford); 2006 Nov 01; 45(11):1356-63. PubMed ID: 16621921
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis.
    Terrier B, Geri G, Chaara W, Allenbach Y, Rosenzwajg M, Costedoat-Chalumeau N, Fouret P, Musset L, Benveniste O, Six A, Klatzmann D, Saadoun D, Cacoub P.
    Arthritis Rheum; 2012 Jun 01; 64(6):2001-11. PubMed ID: 22147555
    [Abstract] [Full Text] [Related]

  • 7. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, Younge BR, Weyand CM, Goronzy JJ.
    Arthritis Rheum; 2006 Oct 01; 54(10):3310-8. PubMed ID: 17009270
    [Abstract] [Full Text] [Related]

  • 8. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.
    Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, Grau JM, Urbano-Márquez A, Colomer D, Kleinman HK, Cid MC.
    Circulation; 2003 May 20; 107(19):2428-34. PubMed ID: 12742994
    [Abstract] [Full Text] [Related]

  • 9. Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.
    Espígol-Frigolé G, Planas-Rigol E, Lozano E, Corbera-Bellalta M, Terrades-García N, Prieto-González S, García-Martínez A, Hernández-Rodríguez J, Grau JM, Cid MC.
    Front Immunol; 2018 May 20; 9():809. PubMed ID: 29731755
    [Abstract] [Full Text] [Related]

  • 10. IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis.
    Ciccia F, Alessandro R, Rizzo A, Raimondo S, Giardina A, Raiata F, Boiardi L, Cavazza A, Guggino G, De Leo G, Salvarani C, Triolo G.
    Ann Rheum Dis; 2013 Feb 20; 72(2):258-64. PubMed ID: 22872024
    [Abstract] [Full Text] [Related]

  • 11. Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis.
    Corbera-Bellalta M, García-Martínez A, Lozano E, Planas-Rigol E, Tavera-Bahillo I, Alba MA, Prieto-González S, Butjosa M, Espígol-Frigolé G, Hernández-Rodríguez J, Fernández PL, Roux-Lombard P, Dayer JM, Rahman MU, Cid MC.
    Ann Rheum Dis; 2014 Mar 20; 73(3):616-23. PubMed ID: 23625984
    [Abstract] [Full Text] [Related]

  • 12. Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events.
    Lozano E, Segarra M, Corbera-Bellalta M, García-Martínez A, Espígol-Frigolé G, Plà-Campo A, Hernández-Rodríguez J, Cid MC.
    Ann Rheum Dis; 2010 Feb 20; 69(2):434-42. PubMed ID: 19289383
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)-17A, IL-22 and transforming growth factor-β1 expression, and increases Foxp3-expressing cells in localized scleroderma.
    Furuzawa-Carballeda J, Ortíz-Ávalos M, Lima G, Jurado-Santa Cruz F, Llorente L.
    Clin Exp Dermatol; 2012 Aug 20; 37(6):599-609. PubMed ID: 22731679
    [Abstract] [Full Text] [Related]

  • 14. Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigole et al.
    Samson M, Audia S, Janikashvili N, Bonnotte B.
    Ann Rheum Dis; 2013 May 20; 72(5):e3. PubMed ID: 23475980
    [No Abstract] [Full Text] [Related]

  • 15. DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis.
    Coit P, De Lott LB, Nan B, Elner VM, Sawalha AH.
    Ann Rheum Dis; 2016 Jun 20; 75(6):1196-202. PubMed ID: 26038090
    [Abstract] [Full Text] [Related]

  • 16. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.
    García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G, Prieto-González S, Butjosa M, Segarra M, Lozano E, Cid MC.
    Arthritis Care Res (Hoboken); 2010 Jun 20; 62(6):835-41. PubMed ID: 20535794
    [Abstract] [Full Text] [Related]

  • 17. Temporal artery biopsy is not required in all cases of suspected giant cell arteritis.
    Quinn EM, Kearney DE, Kelly J, Keohane C, Redmond HP.
    Ann Vasc Surg; 2012 Jul 20; 26(5):649-54. PubMed ID: 22285348
    [Abstract] [Full Text] [Related]

  • 18. Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling.
    Ly KH, Régent A, Molina E, Saada S, Sindou P, Le-Jeunne C, Brézin A, Witko-Sarsat V, Labrousse F, Robert PY, Bertin P, Bourges JL, Fauchais AL, Vidal E, Mouthon L, Jauberteau MO.
    Arthritis Res Ther; 2014 Nov 24; 16(6):487. PubMed ID: 25418464
    [Abstract] [Full Text] [Related]

  • 19. Poor prognosis of visual outcome after visual loss from giant cell arteritis.
    Danesh-Meyer H, Savino PJ, Gamble GG.
    Ophthalmology; 2005 Jun 24; 112(6):1098-103. PubMed ID: 15885780
    [Abstract] [Full Text] [Related]

  • 20. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R.
    Scand J Gastroenterol; 2012 May 24; 47(5):538-47. PubMed ID: 22486187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.